Leitlinie
RWD16 HYPERTENSION CONTROL IN TREATED U.S. CANCER SURVIVORS UNDER THE 2017 ACC/AHA GUIDELINE: AN ANALYSIS OF NHANES 2011-2023
Value in Health · 2026-06 · 29 (6) · S406
DOI: 10.1016/j.jval.2026.03.2005 ↗Kurz gefasst
Leitlinie in der Zeitschrift Value in Health, 2026-06. Verfasst von Hanan Alluhaydan und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Alluhaydan, H., Eguale, T., & Murimi-Worstell, I. (2026). RWD16 HYPERTENSION CONTROL IN TREATED U.S. CANCER SURVIVORS UNDER THE 2017 ACC/AHA GUIDELINE: AN ANALYSIS OF NHANES 2011-2023. Value in Health, 29(6), S406. https://doi.org/10.1016/j.jval.2026.03.2005
Vancouver
Alluhaydan H, Eguale T, Murimi-Worstell I. RWD16 HYPERTENSION CONTROL IN TREATED U.S. CANCER SURVIVORS UNDER THE 2017 ACC/AHA GUIDELINE: AN ANALYSIS OF NHANES 2011-2023. Value in Health. 2026;29(6):S406. doi:10.1016/j.jval.2026.03.2005
BibTeX
@article{Alluhaydan2026,
author = {Alluhaydan, Hanan and Eguale, Tewodros and Murimi-Worstell, Irene},
title = {RWD16 HYPERTENSION CONTROL IN TREATED U.S. CANCER SURVIVORS UNDER THE 2017 ACC/AHA GUIDELINE: AN ANALYSIS OF NHANES 2011-2023},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S406},
doi = {10.1016/j.jval.2026.03.2005}
}
EUVIMED